CMND Company Profile and Key Details

Clearmind Medicine Inc. generated EPS of -$30.37 over the past year. Five-year average earnings growth is 39.75%.

Clearmind Medicine Inc. has 5.38 million shares outstanding. The public float is 5.22 million shares, elevated short interest at 2.74% of float. This equals 142.60 thousand shares. The short ratio is 2.32 days. Institutional investors hold 11.27% of the float. Insiders own 2.8%.

CMND has shown mixed momentum, gaining 22.22% over the past week and -93.11% over the past quarter, though year-to-date performance is up 45.86%. Short-term trend indicators are bullishly aligned (SMA20 -19.27%, SMA50 -43.8%, SMA200 -95.6%). The stock’s 14-day RSI is 25.63 (weak momentum), while the ATR of 0.21 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -97.81% below its high and over 9.58% above its low. Average 10-day trading volume of 6.85 million shares is significantly above the 3-month average of 819.27 thousand, indicating heightened recent market interest.

Clearmind Medicine Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.52. This means the shares are trading below this model’s fair value.

Clearmind Medicine Inc. (NASDAQ:CMND) closed at $1.13 USD, gaining $0.41 (57.03%) from the previous close of $0.72. The stock is currently mid-range between its 52-week high and low $0.59 and $52.40. With a market capitalization of about $154.43 thousand, Clearmind Medicine Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~-1.03). Key stats such as the average daily volume over the past year has been around 837.14 thousand shares, trading with heavier-than-usual volume. Headquartered in Vancouver, BC, Clearmind Medicine Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Adi Zuloff-Shani, the company employs approximately 4 people and listed since November 15, 2022. Clearmind Medicine Inc., a pre-clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems.

Clearmind Medicine Inc. trades at a P/E ratio of -0.11, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.1 suggesting the stock is closer to book value. The P/FCF stands at -0.01, also below market averages.

Our AI price prediction model suggests that Clearmind Medicine Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 7.0%, with price expected at $0.77 by May 01, 2026, within a range of $0.50 to $1.04 3-Month Outlook: Projected fall of -100.0%, reaching $0.00 by July 16, 2026, with a range of $0.00 to $1.03. 1-Year Outlook: Projected gain of 13.95%, with price at $0.82 by April 16, 2027, within a range of $0.00 to $21.05.

Clearmind Medicine Inc. (NASDAQ:CMND) shares are up 45.86% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Clearmind Medicine Inc. trading at a premium to the broader market with a P/E of -0.11. Our AI forecast model points to short-term strength (7.0% over two weeks), a medium-term fall (-100.0% over three months), and a longer-term gain (13.95% over one year), with expected trading ranges indicating moderate volatility.